MX2022000199A - Compuesto de pirazolona y pirimidina, y metodo de preparacion y uso del mismo. - Google Patents

Compuesto de pirazolona y pirimidina, y metodo de preparacion y uso del mismo.

Info

Publication number
MX2022000199A
MX2022000199A MX2022000199A MX2022000199A MX2022000199A MX 2022000199 A MX2022000199 A MX 2022000199A MX 2022000199 A MX2022000199 A MX 2022000199A MX 2022000199 A MX2022000199 A MX 2022000199A MX 2022000199 A MX2022000199 A MX 2022000199A
Authority
MX
Mexico
Prior art keywords
pyrazolone
preparation
pyrimidine compound
use therefor
compound
Prior art date
Application number
MX2022000199A
Other languages
English (en)
Inventor
Qian Wang
Chi Zhang
Lin Zhang
Zhihui Zhang
Sijie Shu
Guangxin Xia
Hui Ge
Bingbin Zhang
Guoyong Huo
Chen Shi
Jiangsong Lou
Yu Mao
Jianxin Yu
Ying Ke
Yanjun Liu
Original Assignee
Shanghai Pharmaceuticals Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Pharmaceuticals Holding Co Ltd filed Critical Shanghai Pharmaceuticals Holding Co Ltd
Publication of MX2022000199A publication Critical patent/MX2022000199A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente invención se describen un compuesto de pirazolona y pirimidina, y un método de preparación y un uso del mismo. En la presente invención se proporciona un compuesto de pirazolona y pirimidina como en la fórmula (I), teniendo dicho compuesto una mejor actividad inhibidora de la quinasa WEE1.
MX2022000199A 2019-06-28 2020-08-28 Compuesto de pirazolona y pirimidina, y metodo de preparacion y uso del mismo. MX2022000199A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910578299 2019-06-28
PCT/CN2020/112034 WO2020259724A2 (zh) 2019-06-28 2020-08-28 一种吡唑酮并嘧啶类化合物、其制备方法及应用

Publications (1)

Publication Number Publication Date
MX2022000199A true MX2022000199A (es) 2022-09-29

Family

ID=73889014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000199A MX2022000199A (es) 2019-06-28 2020-08-28 Compuesto de pirazolona y pirimidina, y metodo de preparacion y uso del mismo.

Country Status (13)

Country Link
US (1) US20220324868A1 (es)
EP (1) EP4008719A4 (es)
JP (1) JP2022539460A (es)
KR (1) KR20230046270A (es)
CN (1) CN112142748B (es)
AU (1) AU2020304472A1 (es)
BR (1) BR112021026620A2 (es)
CA (1) CA3145348A1 (es)
CL (1) CL2021003498A1 (es)
CO (1) CO2022000751A2 (es)
IL (1) IL289395A (es)
MX (1) MX2022000199A (es)
WO (1) WO2020259724A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020009372A (es) 2018-03-09 2020-10-14 Recurium Ip Holdings Llc 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
AU2021271844A1 (en) * 2020-05-15 2022-12-08 Recurium Ip Holdings, Llc Mono- and combination therapies
CN114591334B (zh) * 2020-12-04 2023-10-20 山东轩竹医药科技有限公司 二氢吡唑并嘧啶酮衍生物
WO2022251224A1 (en) * 2021-05-28 2022-12-01 Recurium Ip Holdings, Llc Wee1 inhibitors and methods for treating cancer
CN117751122A (zh) * 2021-08-11 2024-03-22 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
WO2023083194A1 (zh) * 2021-11-09 2023-05-19 杭州格博生物医药有限公司 Wee1蛋白激酶降解剂及其用途
WO2023193789A1 (en) * 2022-04-08 2023-10-12 Beijing Neox Biotech Limited Wee1 degrading compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE353651T1 (de) 2002-07-15 2007-03-15 Janssen Pharmaceutica Nv 3-furylanaloga von toxoflavin als kinaseinhibitoren
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
KR20090121399A (ko) 2007-03-20 2009-11-25 스미스클라인 비참 코포레이션 화합물
CA2681248A1 (en) 2007-03-20 2008-09-25 Smithkline Beecham Corporation Chemical compounds
WO2010067886A1 (en) 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivative
JP2012518598A (ja) 2009-02-25 2012-08-16 Ｍｓｄ株式会社 ピリミドピリミドインダゾール誘導体
AU2016344040B2 (en) * 2015-11-01 2020-12-10 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
ES2902050T3 (es) * 2017-01-23 2022-03-24 Shijiazhuang Sagacity New Drug Dev Co Ltd Derivado 1,2-dihidro-3H-pirazolo[3,4-D]pirimidin-3-ona como inhibidor de Wee1
MX2020001235A (es) * 2017-08-01 2020-07-20 Recurium Ip Holdings Llc Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
WO2019037678A1 (zh) 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
WO2019096322A1 (zh) * 2017-11-20 2019-05-23 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
MX2020009372A (es) * 2018-03-09 2020-10-14 Recurium Ip Holdings Llc 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.

Also Published As

Publication number Publication date
JP2022539460A (ja) 2022-09-09
EP4008719A2 (en) 2022-06-08
AU2020304472A1 (en) 2022-03-03
IL289395A (en) 2022-02-01
CL2021003498A1 (es) 2022-08-19
WO2020259724A2 (zh) 2020-12-30
EP4008719A4 (en) 2023-03-22
CA3145348A1 (en) 2020-12-30
KR20230046270A (ko) 2023-04-05
WO2020259724A3 (zh) 2021-02-18
US20220324868A1 (en) 2022-10-13
CN112142748A (zh) 2020-12-29
CN112142748B (zh) 2023-07-04
BR112021026620A2 (pt) 2022-06-07
CO2022000751A2 (es) 2022-04-29

Similar Documents

Publication Publication Date Title
MX2022000199A (es) Compuesto de pirazolona y pirimidina, y metodo de preparacion y uso del mismo.
AU2018271990A1 (en) Covalent inhibitors of KRAS
PH12018500341A1 (en) Heterocyclic amides as kinase inhibitors
WO2017108723A3 (en) PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
CA2983481A1 (en) Janus kinase inhibitor
EP3980010A4 (en) 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS
TN2018000087A1 (en) New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
WO2007027238A3 (en) Jak kinase inhibitors and their uses
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
CR20210265A (es) Derivados de aminopirimidina/pirazina como inhibidores de ctps1
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
MX2017015837A (es) Procesos e intermediarios para la preparacion de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-piraz ol-1-il]azetidin-3-il}acetonitrilo.
EP3967694A4 (en) TRI-SUBSTITUTED PYRIMIDINE COMPOUND IN POSITIONS 2, 4, 6 USED AS ATR KINASE INHIBITOR
MX2022000243A (es) Nuevos compuestos heterociclicos.
EP4028393A4 (en) 3,5-DISUBSTITUTED PYRAZOLE COMPOUNDS AS KINAS INHIBITORS AND THEIR USES
EP3935037A4 (en) USE OF 8,9-DIHYDROCANNABIDIOL COMPOUNDS
CO2018008253A2 (es) Proceso para preparar compuestos de 7h-pirrolo[2,3-d]pirimidina
MX2019006079A (es) Derivados de oxoisoquinolina novedosos.
MX2021015572A (es) Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones.
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
EP3933044A4 (en) CONVENIENT ENZYME SYNTHESIS OF 3', 3'-CGAMP
AU2019408336A8 (en) Phenylpyrrolidine compound and use thereof
MX2020008488A (es) Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo.
EP3966204A4 (en) SUBSTITUTED 1-AMINO-1H-IMIDAZOLE-5-CARBOXAMIDE AS BRUTON TYROSINE KINASE INHIBITORS